Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers | Zendy

Luís Alou | Zendy; Lorenzo Aguilar | Zendy; David Sevillano | Zendy; María-José Giménez | Zendy; Beatriz Laguna | Zendy; O. Echeverría | Zendy; Antonio J. Carcas | Zendy; Rubin Lubomirov | Zendy; J. Casal | Zendy; J. Prieto | Zendy

Open Access

Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers

Author(s) -

Luís Alou,

Lorenzo Aguilar,

David Sevillano,

María-José Giménez,

Beatriz Laguna,

O. Echeverría,

Antonio J. Carcas,

Rubin Lubomirov,

J. Casal,

J. Prieto

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki071

Subject(s) - streptococcus pneumoniae , amoxicillin , microbiology and biotechnology , antibody , antibacterial agent , chemistry , antibiotics , medicine , biology , immunology

To measure the effect of opsonophagocytosis mediated by complement activated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae strains with reduced susceptibility to beta-lactams (amoxicillin MICs of 2, 4, 8 and 16 mg/L).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research